Lipocine Inc Down 26.17% To $0.31 After Earnings Meet

Lipocine Inc (LPCN) said before open Friday that it lost $0.03 per share in quarter four 2022.

On the revenue line, the company reported $0.00, missing estimates by $1.3 million.

In the same quarter a year ago, the company earned $0.14 per share on revenue of $16.1 million.

The stock is down 26.17% to $0.31 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Lipocine Inc a Bearish Sentiment Rank from InvestorsObserver.

Lipocine Inc has performed a little below average during the past few months. Before the report, Lipocine Inc received a Long-Term Technical Rank by InvestorsObserver of 39, putting it in the bottom half of stocks. The firm set a 52-week low on September 27, 2022 at $0.36 and set a 52-week high on March 24, 2022 at $1.89.

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO, is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.